Advice
in the absence of a submission from the holder of the marketing authorisation:
clascoterone (Winlevi®) is not recommended for use within NHSScotland.
Indication under review: topical treatment of acne vulgaris in patients 12 years of age and older.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice287KB (PDF)
Medicine details
- Medicine name:
- clascoterone (Winlevi)
- SMC ID:
- SMC2894
- Indication:
Topical treatment of acne vulgaris in patients 12 years of age and older
- Pharmaceutical company
- Glenmark Pharmaceuticals Europe Ltd
- BNF chapter
- Skin
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 19 January 2026